What is the current valuation of the Ovarian Cancer Diagnostics Market?

The Ovarian Cancer Diagnostics Market was valued at 2.206 USD Billion in 2024. Read More

What is the projected market size for the Ovarian Cancer Diagnostics Market by 2035?

The market is expected to reach 3.969 USD Billion by 2035. Read More

What is the expected CAGR for the Ovarian Cancer Diagnostics Market during the forecast period?

The market is projected to grow at a CAGR of 5.48% from 2025 to 2035. Read More

What are the main test types contributing to the Ovarian Cancer Diagnostics Market?

The main test types include Biomarker Tests, Imaging Tests, Genetic Tests, and Pathology Tests. Read More

How much revenue did Biomarker Tests generate in 2024?

Biomarker Tests generated approximately 0.662 USD Billion in 2024. Read More

What is the revenue projection for Imaging Tests by 2035?

Imaging Tests are projected to generate around 0.785 USD Billion by 2035. Read More

Which biomarker had the highest revenue in 2024?

The CA-125 biomarker had the highest revenue, generating 0.8 USD Billion in 2024. Read More

What is the expected revenue for Genetic Mutation tests by 2035?

Genetic Mutation tests are expected to generate approximately 0.5 USD Billion by 2035. Read More

What imaging modalities are primarily used in the Ovarian Cancer Diagnostics Market?

Primary imaging modalities include Ultrasound, CT, MRI, and PET. Read More

Ovarian Cancer Diagnostic Market

Q: Which companies are considered key players in the Ovarian Cancer Diagnostics Market?

Key players include Roche, Abbott, Thermo Fisher Scientific, Siemens Healthineers, and Myriad Genetics. Read More

ID: MRFR/HC/27658-HCR

128 Pages

Rahul Gotadki

Last Updated: May 14, 2026

Ovarian Cancer Diagnostics Market Research Report: Size, Share, Trend Analysis By Test Type (Biomarker Tests, Imaging Tests, Genetic Tests, Pathology Tests), By Biomarker (CA-125, HE4, ROMA, OVX1, PAX2, MMP7), By Imaging modality (Ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), By Genetic mutation (BRCA1, BRCA2, TP53, PTEN, ARID1A, CHEK2) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Ovarian Cancer Diagnostic Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.48%

2024 Market Size$ 2.21 Billion

2025 Market Size$ 2.33 Billion

2035 Market Size$ 3.97 Billion

Key Players

Roche

Abbott

Thermo Fisher Scientific

Siemens Healthineers

Bristol-Myers Squibb

Myriad Genetics

Trends

Technological Advancements in Diagnostics
Increased Focus on Early Detection
Personalized Medicine Approaches

Opportunities

Increased Awareness and Education
Government Initiatives and Funding
Rising Incidence of Ovarian Cancer

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Test Type (USD Billion)
  1. 4.1.1 Biomarker Tests
  2. 4.1.2 Imaging Tests
  3. 4.1.3 Genetic Tests
  4. 4.1.4 Pathology Tests
2. 4.2 Healthcare, BY Biomarker (USD Billion)
  1. 4.2.1 CA-125
  2. 4.2.2 HE4
  3. 4.2.3 ROMA
  4. 4.2.4 OVX1
  5. 4.2.5 PAX2
  6. 4.2.6 MMP7
3. 4.3 Healthcare, BY Imaging Modality (USD Billion)
  1. 4.3.1 Ultrasound
  2. 4.3.2 Computed Tomography (CT)
  3. 4.3.3 Magnetic Resonance Imaging (MRI)
  4. 4.3.4 Positron Emission Tomography (PET)
4. 4.4 Healthcare, BY Genetic Mutation (USD Billion)
  1. 4.4.1 BRCA1
  2. 4.4.2 BRCA2
  3. 4.4.3 TP53
  4. 4.4.4 PTEN
  5. 4.4.5 ARID1A
  6. 4.4.6 CHEK2
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Abbott (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Thermo Fisher Scientific (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Siemens Healthineers (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Myriad Genetics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Guardant Health (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 F. Hoffmann-La Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Genomic Health (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TEST TYPE
4. 6.4 US MARKET ANALYSIS BY BIOMARKER
5. 6.5 US MARKET ANALYSIS BY IMAGING MODALITY
6. 6.6 US MARKET ANALYSIS BY GENETIC MUTATION
7. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE
8. 6.8 CANADA MARKET ANALYSIS BY BIOMARKER
9. 6.9 CANADA MARKET ANALYSIS BY IMAGING MODALITY
10. 6.10 CANADA MARKET ANALYSIS BY GENETIC MUTATION
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY BIOMARKER
14. 6.14 GERMANY MARKET ANALYSIS BY IMAGING MODALITY
15. 6.15 GERMANY MARKET ANALYSIS BY GENETIC MUTATION
16. 6.16 UK MARKET ANALYSIS BY TEST TYPE
17. 6.17 UK MARKET ANALYSIS BY BIOMARKER
18. 6.18 UK MARKET ANALYSIS BY IMAGING MODALITY
19. 6.19 UK MARKET ANALYSIS BY GENETIC MUTATION
20. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY BIOMARKER
22. 6.22 FRANCE MARKET ANALYSIS BY IMAGING MODALITY
23. 6.23 FRANCE MARKET ANALYSIS BY GENETIC MUTATION
24. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY BIOMARKER
26. 6.26 RUSSIA MARKET ANALYSIS BY IMAGING MODALITY
27. 6.27 RUSSIA MARKET ANALYSIS BY GENETIC MUTATION
28. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE
29. 6.29 ITALY MARKET ANALYSIS BY BIOMARKER
30. 6.30 ITALY MARKET ANALYSIS BY IMAGING MODALITY
31. 6.31 ITALY MARKET ANALYSIS BY GENETIC MUTATION
32. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY BIOMARKER
34. 6.34 SPAIN MARKET ANALYSIS BY IMAGING MODALITY
35. 6.35 SPAIN MARKET ANALYSIS BY GENETIC MUTATION
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY IMAGING MODALITY
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY GENETIC MUTATION
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE
42. 6.42 CHINA MARKET ANALYSIS BY BIOMARKER
43. 6.43 CHINA MARKET ANALYSIS BY IMAGING MODALITY
44. 6.44 CHINA MARKET ANALYSIS BY GENETIC MUTATION
45. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE
46. 6.46 INDIA MARKET ANALYSIS BY BIOMARKER
47. 6.47 INDIA MARKET ANALYSIS BY IMAGING MODALITY
48. 6.48 INDIA MARKET ANALYSIS BY GENETIC MUTATION
49. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY BIOMARKER
51. 6.51 JAPAN MARKET ANALYSIS BY IMAGING MODALITY
52. 6.52 JAPAN MARKET ANALYSIS BY GENETIC MUTATION
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY IMAGING MODALITY
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY GENETIC MUTATION
57. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY BIOMARKER
59. 6.59 MALAYSIA MARKET ANALYSIS BY IMAGING MODALITY
60. 6.60 MALAYSIA MARKET ANALYSIS BY GENETIC MUTATION
61. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY BIOMARKER
63. 6.63 THAILAND MARKET ANALYSIS BY IMAGING MODALITY
64. 6.64 THAILAND MARKET ANALYSIS BY GENETIC MUTATION
65. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY BIOMARKER
67. 6.67 INDONESIA MARKET ANALYSIS BY IMAGING MODALITY
68. 6.68 INDONESIA MARKET ANALYSIS BY GENETIC MUTATION
69. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY BIOMARKER
71. 6.71 REST OF APAC MARKET ANALYSIS BY IMAGING MODALITY
72. 6.72 REST OF APAC MARKET ANALYSIS BY GENETIC MUTATION
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY BIOMARKER
76. 6.76 BRAZIL MARKET ANALYSIS BY IMAGING MODALITY
77. 6.77 BRAZIL MARKET ANALYSIS BY GENETIC MUTATION
78. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY BIOMARKER
80. 6.80 MEXICO MARKET ANALYSIS BY IMAGING MODALITY
81. 6.81 MEXICO MARKET ANALYSIS BY GENETIC MUTATION
82. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY BIOMARKER
84. 6.84 ARGENTINA MARKET ANALYSIS BY IMAGING MODALITY
85. 6.85 ARGENTINA MARKET ANALYSIS BY GENETIC MUTATION
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMAGING MODALITY
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY GENETIC MUTATION
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY IMAGING MODALITY
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY GENETIC MUTATION
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY IMAGING MODALITY
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY GENETIC MUTATION
99. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY BIOMARKER
101. 6.101 REST OF MEA MARKET ANALYSIS BY IMAGING MODALITY
102. 6.102 REST OF MEA MARKET ANALYSIS BY GENETIC MUTATION
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY BIOMARKER, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY BIOMARKER, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY IMAGING MODALITY, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY IMAGING MODALITY, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY GENETIC MUTATION, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY GENETIC MUTATION, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.2.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.2.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.3.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.3.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.4.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.4.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.5.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.5.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.6.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.6.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.7.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.7.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.8.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.8.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.9.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.9.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.10.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.10.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.11.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.11.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.12.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.12.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.13.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.13.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.14.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.14.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.15.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.15.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.16.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.16.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.17.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.17.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.18.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.18.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.19.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.19.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.20.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.20.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.21.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.21.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.22.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.22.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.23.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.23.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.24.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.24.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.25.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.25.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.26.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.26.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.27.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.27.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.28.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.28.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.29.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.29.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY BIOMARKER, 2025-2035 (USD Billion)
  3. 7.30.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  4. 7.30.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Ovarian Cancer Diagnostic Market Segmentation

Ovarian Cancer Diagnostic Market By Test Type (USD Billion, 2025-2035)

Biomarker Tests
Imaging Tests
Genetic Tests
Pathology Tests

Ovarian Cancer Diagnostic Market By Biomarker (USD Billion, 2025-2035)

CA-125
HE4
ROMA
OVX1
PAX2
MMP7

Ovarian Cancer Diagnostic Market By Imaging Modality (USD Billion, 2025-2035)

Ultrasound
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET)

Ovarian Cancer Diagnostic Market By Genetic Mutation (USD Billion, 2025-2035)

BRCA1
BRCA2
TP53
PTEN
ARID1A
CHEK2

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”